Novo Nordisk buys rights to NASH drug from Japan's UBE

Novo Nordisk has acquired rights to a preclinical drug that could be used to treat non-alcoholic steatohepatitis (NASH), the fatty liver disease that could generate billions of dollars for

Novo Nordisk builds in haemophilia with Bluebird Bio gene ed...

How to make digital adoption a smooth journey

Four big pharma experts explain the challenges companies face in adopting digital tech and what trends are likely to drive digital commercial strategies in the next few years.

Novo’s new oral GLP-1 Rybelsus still has obstacles to overco...

The Pharma Comms Impact Conference - For Internal & External

20 Pharmaceutical Communications Senior Speakers, 1 Day

Novo and Sanofi make case for hypo-reducing insulins at EASD

Novo Nordisk and Sanofi have gone head-to-head at this week’s European diabetes conference, with the two arch rivals trying to make the case for their competing insulins and their ability t